Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor.

被引：1

作者：

Rodon, Jordi ^{[1
]}

Juric, Dejan ^{[2
]}

Gonzalez-Angulo, Ana-Maria ^{[3
]}

Bendell, Johanna ^{[4
]}

Berlin, Jordan ^{[5
]}

Bootle, Douglas ^{[6
]}

Gravelin, Kathlene ^{[7
]}

Huang, Alan ^{[7
]}

Derti, Adnan ^{[7
]}

Lehar, Joseph ^{[7
]}

Wuerthner, Jens ^{[6
]}

Boehm, Markus ^{[6
]}

van Allen, Eliezer ^{[8
]}

Wagle, Nikhil ^{[8
]}

Garraway, Levi A. ^{[8
]}

Yelensky, Roman ^{[9
]}

Stephens, Philip J. ^{[9
]}

Miller, Vincent A. ^{[9
]}

Schlegel, Robert ^{[7
]}

Quadt, Cornelia ^{[6
]}

Baselga, Jose ^{[10
]}

机构：

[1] Vail dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain

[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Sarah Cannon Res Inst, Nashville, TN USA

[5] Vanderbilt Canc Ctr, Nashville, TN USA

[6] Novartis Pharma AG, Oncol Translat Med, Basel, Switzerland

[7] NIBR Inc, Oncol Translat Med, Cambridge, MA USA

[8] Broad Inst, Cambridge, MA USA

[9] Fdn Med Inc, Cambridge, MA USA

[10] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

CANCER RESEARCH | 2013年 / 73卷 / 08期

关键词：

D O I：

10.1158/1538-7445.AM2013-LB-65

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LB65

引用

页数：2

共 44 条

[41] Phase I trial of daily PI3Kα inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC).
Shah, Payal Deepak
Modi, Shanu
Datko, Farrah Mikhail
Moynahan, Mary Ellen
Zamora, Stephen
D'Andrea, Gabriella
Lake, Diana
Goldfarb, Sharl Beth
Patil, Sujata
Singh, Sharat
Langley, Emma J.
Kim, Phillip Sangwook
Covey, Anne M.
Caravella, Betty Ann
Berger, Michael F.
Lacouture, Mario E.
Hudis, Clifford A.
Baselga, Jose
Chandarlapaty, Sarat
Dickler, Maura N.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[42] Phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients with PIK3CA-altered and wild type ER+/HER2-locally advanced or metastatic breast cancer
Janku, Filip
Juric, Dejan
Cortes, Javier
Rugo, Hope
Burris, Howard A.
Schuler, Martin
Deschler-Baier, Barbara
Middleton, Mark R.
Gil-Martin, Marta
Berlin, Jordan
Winer, Eric
Bootle, Douglas
Blumenstein, Lars
Demanse, David
Coughlin, Christina
Quadt, Cornelia
Baselga, Jose
CANCER RESEARCH, 2015, 75
[43] Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients with PIK3CA mutant advanced solid tumors: preliminary efficacy and safety in patients with PIK3CA mutant ER -positive (ER plus ) metastatic breast cancer (MBC)
Juric, D.
Argiles, G.
Burns, H. A.
Gonzalez-Angulo, A. M.
Saura, C.
Quadt, C.
Douglas, M.
Demanse, D.
De Buck, S.
Baselga, J.
CANCER RESEARCH, 2012, 72
[44] Clinical and biomarker results from phase I/II study of PI3K inhibitor BYL 719 (alpelisib) plus nab-paclitaxel in HER2-negative metastatic breast cancer
Sharma, Priyanka
Abramson, Vandana Gupta
O'Dea, Anne
Pathak, Harsh B.
Pessetto, Ziyan Y.
Wang, Yen Y.
Finke, Karissa
Hoffmann, Marc Steven
Elia, Manana
Lewis, Sharon
Scott, Jecinta
De Jong, Jilliann
Urban, Julia
Heldstab, Jaimie
LaFaver, Stephanie
Williamson, Stephen K.
Reed, Greg
Kimler, Bruce F.
Khan, Qamar J.
Godwin, Andrew K.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →